Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial-Reference-Cited by-同舟云学术

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Published:2016-05 Issue:5 Volume:17 Page:577-589
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Park Keunchil,Tan Eng-Huat,O'Byrne Ken,Zhang Li,Boyer Michael,Mok Tony,Hirsh Vera,Yang James Chih-Hsin,Lee Ki Hyeong,Lu Shun,Shi Yuankai,Kim Sang-We,Laskin Janessa,Kim Dong-Wan,Arvis Catherine Dubos,Kölbeck Karl,Laurie Scott A,Tsai Chun-Ming,Shahidi Mehdi,Kim Miyoung,Massey Dan,Zazulina Victoria,Paz-Ares Luis

Publisher

Elsevier BV

Subject

Oncology

Reference33 articles.

1. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

2. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

3. Epidermal growth factor receptor mutations in lung cancer;Sharma;Nat Rev Cancer,2007

4. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

5. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2010

Cited by 978 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development;Cancer Treatment Reviews;2024-09

2. A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations;International Journal of Clinical Oncology;2024-08-27

3. Efficacy analysis of immunotherapy‑based combinations for patients with EGFR‑mutant advanced non‑small cell lung cancer after TKI failure;Oncology Letters;2024-08-20

4. Treatment sequences in EGFR mutant advanced NSCLC;Lung Cancer;2024-08

5. Evaluation of drug resistance for EGFR-TKIs in lung cancer via multicellular lung-on-a-chip;European Journal of Pharmaceutical Sciences;2024-08